Patents by Inventor Matthias Klinger
Matthias Klinger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20170327581Abstract: The present invention relates in essence to a compound which decreases or inhibits the binding of mammalian T-cells to mammalian endothelial cells for use in a method of prophylaxis and/or amelioration and/or treatment of clinical adverse events caused by therapy which comprises re-directing of T-cells against target cells in a patient. Methods of treatment of patients having or being at risk of clinical adverse events caused by therapy which comprises re-directing of T-cells against target cells are also contemplated.Type: ApplicationFiled: May 24, 2017Publication date: November 16, 2017Inventors: Peter Kufer, Dirk Nagorsen, Juergen Scheele, Gerhard Zugmaier, Matthias Klinger, Patrick Hoffmann, Virginie Naegele, Elaine-Pashupati Dopfer
-
Publication number: 20170275373Abstract: The present invention provides to a bispecific single chain antibody construct binding to a target cell surface antigen via a first binding domain and to the T cell surface antigen CD3 via a second binding domain, the construct comprising two FcRn binding peptides. Moreover, the invention provides a nucleic acid molecule encoding the antibody construct, a vector comprising said nucleic acid molecule and a host cell transformed or transfected with said vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.Type: ApplicationFiled: July 31, 2015Publication date: September 28, 2017Inventors: Peter Kufer, Patrick Hoffmann, Markus Münz, Matthias Klinger, Elaine-Pashupati Dopfer, Elisabeth Nahrwold
-
Patent number: 9688760Abstract: The present invention relates in essence to use of a compound, which decreases or inhibits the binding of mammalian T-cells to mammalian endothelial cells for use in a method of prophylaxis and/or amelioration and/or treatment of clinical adverse events caused by a therapy which comprises re-directing of T-cells against target cells in a patient. Such a therapy includes, but is not limited to, treatment with an antibody comprising a CD3 binding domain, such as a CD20×CD3 or a CD19×CD3 bispecific single chain antibody, e.g., blinatumomab (MT-103). Methods of treatment of patients having or being at risk of clinical adverse events caused by therapy which comprises re-directing of T-cells against target cells are also contemplated, as are methods of identifying a compound for administration in the methods of prophylaxis, amelioration and/or treatment.Type: GrantFiled: February 8, 2014Date of Patent: June 27, 2017Assignee: AMGEN RESEARCH (MUNICH) GMBHInventors: Peter Kufer, Dirk Nagorsen, Juergen Scheele, Gerhard Zugmaier, Matthias Klinger, Patrick Hoffmann, Virginie Naegele, Elaine-Pashupati Dopfer
-
Patent number: 9587036Abstract: The present invention relates to a bispecific single chain antibody molecule comprising a first binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3 epsilon chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain capable of binding to prostate-specific membrane antigen (PSMA). The invention also provides nucleic acids encoding said bispecific single chain antibody molecule as well as vectors and host cells and a process for its production. The invention further relates to pharmaceutical compositions comprising said bispecific single chain antibody molecule and medical uses of said bispecific single chain antibody molecule.Type: GrantFiled: April 1, 2011Date of Patent: March 7, 2017Assignee: AMGEN RESEARCH (MUNICH) GMBHInventors: Peter Kufer, Ralf Lutterbuese, Matthias Klinger, Petra Fluhr, Doris Rau, Susanne Hausmann, Carola Steiger, Tobias Raum, Patrick Hoffmann, Roman Kischel, Evelyne Schaller, Susanne Mangold
-
Patent number: 9486475Abstract: The present invention relates to a pentosanpolysulfate (PPS) or a pharmaceutically acceptable salt thereof for use in the amelioration, treatment, or prevention of adverse neurological events caused by administering an antibody or fragment thereof comprising a CD3 binding domain, including a CD19 x CD3 bispecific single chain antibody, such as blinatumomab. PPS is a semi-synthetically produced heparin-like macromolecular carbohydrate derivative, which chemically and structurally resembles glycosaminoglycans. Kits comprising a PPS, an antibody or fragment thereof comprising a CD3 binding domain, and instructions for administration, which indicate that the PPS is to be employed for the amelioration, treatment or prevention of adverse neurological events caused by administering the antibody or fragment thereof comprising said CD3 binding domain, are also disclosed.Type: GrantFiled: February 8, 2014Date of Patent: November 8, 2016Assignee: AMGEN RESEARCH (MUNICH) GMBHInventors: Peter Kufer, Dirk Nagorsen, Juergen Scheele, Gerhard Zugmaier, Matthias Klinger, Patrick Hoffmann, Virginie Naegele, Elaine-Pashupati Dopfer
-
Publication number: 20160152707Abstract: The present invention relates to a polypeptide comprising a first human binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3 epsilon (CD3?) chain and a second binding domain capable of binding to EGFR, Her2/neu or IgE of a human and/or a non-chimpanzee primate as well as to a process for the production of the mentioned polypeptide. The invention further relates to nucleic acids encoding for the polypeptide, to vectors comprising the same and to host cells comprising the vector. In another aspect, the invention provides for a pharmaceutical composition comprising the mentioned polypeptide and medical uses of the polypeptide.Type: ApplicationFiled: November 20, 2015Publication date: June 2, 2016Inventors: Peter Kufer, Tobias Raum, Roman Kischel, Ralf Lutterbüse, Patrick Hoffmann, Matthias Klinger, Doris Rau, Susanne Mangold
-
Publication number: 20140227272Abstract: The present invention relates in essence to a compound which decreases or inhibits the binding of mammalian T-cells to mammalian endothelial cells for use in a method of prophylaxis and/or amelioration and/or treatment of clinical adverse events caused by therapy which comprises re-directing of T-cells against target cells in a patient. Methods of treatment of patients having or being at risk of clinical adverse events caused by therapy which comprises re-directing of T-cells against target cells are also contemplated.Type: ApplicationFiled: February 8, 2014Publication date: August 14, 2014Applicant: AMGEN RESEARCH (MUNICH) GMBHInventors: Peter Kufer, Dirk Nagorsen, Juergen Scheele, Gerhard Zugmaier, Matthias Klinger, Patrick Hoffmann, Virginie Naegele, Elaine-Pashupati Dopfer
-
Publication number: 20140228316Abstract: The present invention relates to a PPS for use in the amelioration, treatment or prophylaxis of neurological adverse events caused by a CD3 binding domain. Kits comprising a PPS, a CD3 binding domain and instructions for use which indicate that the PPS is to be employed for the treatment amelioration and/or prophylaxis of neurological adverse events caused by said CD3 binding domain, are also disclosed.Type: ApplicationFiled: February 8, 2014Publication date: August 14, 2014Applicant: AMGEN RESEARCH (MUNICH) GMBHInventors: Peter Kufer, Dirk Nagorsen, Juergen Scheele, Gerhard Zugmaier, Matthias Klinger, Patrick Hoffmann, Virginie Naegele, Elaine-Pashupati Dopfer
-
Publication number: 20130129730Abstract: The present invention relates to a bispecific single chain antibody molecule comprising a first binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3 epsilon chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain capable of binding to prostate-specific membrane antigen (PSMA). The invention also provides nucleic acids encoding said bispecific single chain antibody molecule as well as vectors and host cells and a process for its production. The invention further relates to pharmaceutical compositions comprising said bispecific single chain antibody molecule and medical uses of said bispecific single chain antibody molecule.Type: ApplicationFiled: April 1, 2011Publication date: May 23, 2013Inventors: Peter Kufer, Ralf Lutterbuese, Matthias Klinger, Petra Fluhr, Doris Rau, Susanne Hausmann, Carole Steiger, Tobias Raum, Patrick Hoffmann, Roman Kischel, Evelyne Schaller, Susanne Mangold
-
Publication number: 20130095103Abstract: Provided are pharmaceutical means and methods for the prevention, treatment or amelioration of indolent or aggressive B cell non-Hodgkin lymphoma (B NHL) and B cell leukemia comprising the administration of a bispecific single chain antibody construct to a subject in the need thereof and the use of said bispecific single chain antibody construct for the preparation of a pharmaceutical composition for the prevention, treatment or amelioration of indolent or aggressive B cell non-Hodgkin lymphoma (B NHL) and B cell leukemia, whereby said construct is to be administered for at least 1 week in specified daily doses. Moreover, the invention relates to kits comprising a bispecific single chain antibody construct to be used in accordance with this invention.Type: ApplicationFiled: August 26, 2011Publication date: April 18, 2013Inventors: Patrick Baeuerle, Peter Kufer, Matthias Klinger, Eugen Leo
-
Publication number: 20120244162Abstract: The present invention relates to a polypeptide comprising a first human binding domain capbable of binding to an epitope of human and non-chimpanzee CD3? (epsilon) chain and a second binding domain capable of binding to EGFR, Her2/neu or IgE of a human and/or a non-chimpanzee primate as well as to a process for the production of the mentioned polypeptide. The invention further relates to nucleic acid sequences encoding the polypeptide, to vectors comprising the nucleic acid sequences and to host cells comprising the nucleic acid sequences or vectors containing the nucleic acid sequences. In another aspect, the invention provides for a pharmaceutical composition comprising the polypeptide and methods of medical treatment or use of the polypeptide.Type: ApplicationFiled: February 29, 2012Publication date: September 27, 2012Inventors: Peter KUFER, Tobias Raum, Roman Kischel, Ralf Lutterbüse, Patrick Hoffmann, Matthias Klinger, Doris Rau, Susanne Mangold
-
Publication number: 20120034228Abstract: The present invention relates to a bispecific single chain antibody molecule comprising a first binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3 epsilon chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain capable of binding to an antigen selected from the group consisting of Prostate Stem Cell Antigen (PSCA), B-Lymphocyte antigen CD19 (CD19), hepatocyte growth factor receptor (C-MET), Endosialin, the EGF-like domain 1 of EpCAM, encoded by exon 2, Fibroblast activation protein alpha (FAP alpha) and Insulin-like growth factor I receptor (IGF-IR or IGF-1R). The invention also provides nucleic acids encoding said bispecific single chain antibody molecule as well as vectors and host cells and a process for its production.Type: ApplicationFiled: October 1, 2009Publication date: February 9, 2012Inventors: Peter Kufer, Tobias Raum, Roman Kischel, Ralf Lutterbüse, Patrick Hoffmann, Doris Rau, Matthias Klinger, Susanne Mangold, Claudia Blümel
-
Publication number: 20110293619Abstract: The present invention relates to a bispecific single chain antibody molecule comprising a first binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3 epsilon chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain capable of binding to prostate-specific membrane antigen (PSMA). The invention also provides nucleic acids encoding said bispecific single chain antibody molecule as well as vectors and host cells and a process for its production. The invention further relates to pharmaceutical compositions comprising said bispecific single chain antibody molecule and medical uses of said bispecific single chain anti-body molecule.Type: ApplicationFiled: October 1, 2009Publication date: December 1, 2011Inventors: Peter Kufer, Tobias Raum, Roman Kischel, Ralf Lütterbuse, Patrick Hoffmann, Doris Rau, Susanne Mangold, Matthias Klinger, Evelyne aschaller, Susanne Hausmann, Petra Fluhr, Carola Steiger
-
Patent number: 8007796Abstract: The invention relates to pharmaceutical means and methods for the prevention, treatment or amelioration of indolent or aggressive B cell non-Hodgkin lymphoma (B NHL) and B cell leukemia comprising the administration of a bispecific single chain antibody construct to a subject and the use of the bispecific single chain antibody construct for the preparation of a pharmaceutical composition for the prevention, treatment or amelioration of indolent or aggressive B cell non-Hodgkin lymphoma (B NHL) and B cell leukemia. The construct is to be administered for at least 1 week in specified daily doses. Moreover, the invention relates to kits comprising a bispecific single chain antibody construct to be used in accordance with this invention.Type: GrantFiled: November 29, 2006Date of Patent: August 30, 2011Assignee: Micromet AGInventors: Patrick Baeuerle, Peter Kufer, Matthias Klinger, Eugen Leo
-
Publication number: 20100183615Abstract: The present invention relates to a polypeptide comprising a first human binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3 (epsilon) chain and a second binding domain capable of binding to EGFR, Her2/neu or IgE of a human and/or a non-chimpanzee primate as well as to a process for the production of the mentioned polypeptide. The invention further relates to nucleic acids encoding for the polypeptide, to vectors comprising the same and to host cells comprising the vector. In another aspect, the invention provides for a pharmaceutical composition comprising the mentioned polypeptide and medical uses of the polypeptide.Type: ApplicationFiled: April 3, 2008Publication date: July 22, 2010Applicant: MICROMET AGInventors: Peter Kufer, Tobias Raum, Roman Kischel, Ralf Lutterbuese, Patrick Hoffmann, Matthias Klinger, Doris Rau, Susanne Mangold
-
Publication number: 20100150918Abstract: The present invention relates to a polypeptide comprising a human binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3 (epsilon) chain as well as to a process for the production of the mentioned polypeptide. The invention further relates to nucleic acids encoding for the polypeptide, to vectors comprising the same and to host cells comprising the vector. In another aspect, the invention provides for a pharmaceutical composition comprising the mentioned polypeptide and medical uses of the polypeptide. In a further aspect the invention provides a method for the identification of polypeptides comprising a cross-species specific binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3? (CD3 epsilon).Type: ApplicationFiled: April 3, 2008Publication date: June 17, 2010Applicant: MICROMET AGInventors: Peter Kufer, Tobias Raum, Roman Kischel, Ralf Lutterbuese, Patrick Hoffmann, Matthias Klinger, Doris Rau, Susanne Mangold
-
Publication number: 20090291072Abstract: Provided are pharmaceutical means and methods for the prevention, treatment or amelioration of indolent or aggressive B cell non-Hodgkin lymphoma (B NHL) and B cell leukemia comprising the administration of a bispecific single chain antibody construct to a subject in the need thereof and the use of said bispecific single chain antibody construct for the preparation of a pharmaceutical composition for the prevention, treatment or amelioration of indolent or aggressive B cell non-Hodgkin lymphoma (B NHL) and B cell leukemia, whereby said construct is to be administered for at least 1 week in specified daily doses. Moreover, the invention relates to kits comprising a bispecific single chain antibody construct to be used in accordance with this invention.Type: ApplicationFiled: November 29, 2006Publication date: November 26, 2009Inventors: Patrick Baeuerle, Peter Kufer, Matthias Klinger, Eugen Leo